Anabolic Steroids Blog - iSteroids . com » New Approach for preventing transplant rejection

New Approach for preventing transplant rejection

New Approach for preventing transplant rejection According to researchers at the University of North Carolina at Chapel Hill School of Medicine and the UNC Lineberger Comprehensive Cancer Center, a subset of cells – named TH17 cells - can help in uncovering the mechanisms that result in graft-versus-host disease to promote treatments without the harmful side effects of traditional immunosuppressive therapy.

The study results appeared in the Feb. 5, 2009, issue of Blood, the journal of the American Society of Hematology.

It is believed that the study finding could help chart a course for completely new therapies that can inhibit graft-versus-host disease.

From News-Medical.Net:

The UNC study has identified a subset of cells – named TH17 cells – that can bring about the condition. Until now, without a clear understanding of the disease, clinicians have had little choice but to treat transplant patients with toxic regimens of steroids and immunosuppressive drugs.

“Our hope is that uncovering the mechanisms that cause graft-versus-host disease will allow for treatments that specifically target its causes and do not have the harmful side effects of traditional immunosuppressive therapy,” said study lead author Jonathan S. Serody, M.D., a member of the Lineberger Center and the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology at UNC. The results of the study appeared in the Feb. 5, 2009, issue of Blood, the journal of the American Society of Hematology.

Graft-versus-host disease (GVHD) is a serious complication of transplants that occurs when the donor’s marrow (graft) produces immune cells that attack multiple organs of the recipient (host), typically the skin, gastrointestinal tract and liver.

Study lead author Jonathan S. Serody, M.D., a member of the Lineberger Center and the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology at UNC, remarked that new drugs are expected to appear at the health market in the next five years for treating immune-based skin diseases.